ANIP ANI PHARMACEUTICALS INC
Nasdaq · SEC CIK 1023024 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $14.87M 41 sales by 12 insiders
- Filings on record
- 320 since 2021-09-10, latest 2026-09-16 16:20
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Lalwani Nikhil | Pres, CEO, Dir | — | $5.05M |
| Walsh Patrick D | Dir | — | $2.32M |
| CAREY STEPHEN P. | SVP, CFO | — | $1.78M |
| Mutz Christopher | HEAD OF RARE DISEASE | — | $1.64M |
| Gassert Chad | SVP - CORP. DEV, STRATEGY | — | $1.31M |
| Davis Krista | SVP, Chief HR Off | — | $918.6K |
| Gutwerg Ori | SVP, GENERICS | — | $621.4K |
| Cook Meredith | SVP, GC, SEC | — | $453.9K |
| Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | — | $393.8K |
| HAUGHEY THOMAS | Dir | — | $161.8K |
Transactions 356
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2024-04-22 | 2024-04-18+ | ANIP | Shanmugam Muthusamy | HEAD OF R, D, COO-NOVITIUM OPS, Dir | S - Sale | $65.10 | -27.2K | 799.4K | -3% | -$1.77M |
| MI | 2024-04-17 | 2024-04-15+ | ANIP | Shanmugam Muthusamy | HEAD OF R, D, COO-NOVITIUM OPS, Dir | S - Sale | $65.91 | -22.8K | 825.2K | -3% | -$1.50M |
| 2024-04-15 | 2024-04-12 | ANIP | Cook Meredith | SVP, GC, SEC | S - Sale | $67.79 | -250 | 59.7K | -0.4% | -$16.9K | |
| 2024-04-11 | 2024-04-10 | ANIP | CAREY STEPHEN P. | SVP, CFO | F - Tax | $66.96 | -4,534 | 167.0K | -3% | -$303.6K | |
| 2024-04-11 | 2024-04-10 | ANIP | Marken James G. | SVP OPS, PROD DEV | F - Tax | $66.96 | -2,799 | 116.0K | -2% | -$187.4K | |
| I | 2024-04-02 | 2024-04-01 | ANIP | Gassert Chad | SVP - CORP. DEV, STRATEGY | S - Sale | $67.25 | -20.0K | 253.2K | -7% | -$1.34M |
| 2024-03-25 | 2024-03-23 | ANIP | Marken James G. | SVP OPS, PROD DEV | F - Tax | $69.58 | -3,653 | 118.8K | -3% | -$254.2K | |
| 2024-03-25 | 2024-03-23 | ANIP | Lalwani Nikhil | Pres, CEO, Dir | F - Tax | $69.58 | -17.5K | 394.2K | -4% | -$1.21M | |
| 2024-03-25 | 2024-03-23 | ANIP | CAREY STEPHEN P. | SVP, CFO | F - Tax | $69.58 | -6,210 | 171.5K | -3% | -$432.1K | |
| I | 2024-03-13 | 2024-03-11 | ANIP | Gassert Chad | SVP - CORP. DEV, STRATEGY | S - Sale | $65.81 | -20.0K | 273.2K | -7% | -$1.32M |
| 2024-03-13 | 2024-03-13 | ANIP | Cook Meredith | SVP, GC, SEC | S - Sale | $66.54 | -250 | 60.0K | -0.4% | -$16.6K | |
| 2024-03-11 | 2024-03-11 | ANIP | CAREY STEPHEN P. | SVP, CFO | S - Sale | $65.55 | -7,787 | 177.7K | -4% | -$510.4K | |
| 2024-03-11 | 2024-03-07 | ANIP | CAREY STEPHEN P. | SVP, CFO | F - Tax | $66.71 | -4,216 | 185.5K | -2% | -$281.2K | |
| I | 2024-03-11 | 2024-03-08 | ANIP | Shanmugam Muthusamy | HEAD OF R, D, COO-NOVITIUM OPS, Dir | S - Sale | $67.17 | -10.0K | 832.6K | -1% | -$671.7K |
| M | 2024-03-08 | 2024-03-06+ | ANIP | Lalwani Nikhil | Pres, CEO, Dir | S - Sale | $66.10 | -45.3K | 445.0K | -9% | -$2.99M |
| 2024-03-08 | 2024-03-07 | ANIP | Lalwani Nikhil | Pres, CEO, Dir | F - Tax | $66.71 | -17.1K | 427.9K | -4% | -$1.14M | |
| MI | 2024-03-07 | 2024-03-05+ | ANIP | Shanmugam Muthusamy | HEAD OF R, D, COO-NOVITIUM OPS, Dir | S - Sale | $65.77 | -40.0K | 842.6K | -5% | -$2.63M |
| 2024-03-07 | 2024-03-07 | ANIP | Mutz Christopher | HEAD OF RARE DISEASE | F - Tax | $66.71 | -2,110 | 85.3K | -2% | -$140.8K | |
| 2024-03-07 | 2024-03-07 | ANIP | Marken James G. | SVP OPS, PROD DEV | S - Sale | $66.37 | -24.3K | 124.5K | -16% | -$1.62M | |
| 2024-03-07 | 2024-03-07 | ANIP | Marken James G. | SVP OPS, PROD DEV | F - Tax | $66.71 | -2,034 | 122.5K | -2% | -$135.7K | |
| 2024-03-07 | 2024-03-07 | ANIP | Gutwerg Ori | SVP, GENERICS | F - Tax | $66.71 | -2,494 | 80.2K | -3% | -$166.4K | |
| 2024-03-06 | 2024-03-04 | ANIP | Pera Antonio R | Dir | S - Sale | $65.20 | -7,000 | 26.6K | -21% | -$456.4K | |
| 2024-03-06 | 2024-03-05 | ANIP | Mutz Christopher | HEAD OF RARE DISEASE | S - Sale | $66.00 | -5,000 | 87.4K | -5% | -$330.0K | |
| 2024-03-01 | 2024-02-29 | ANIP | Shanmugam Muthusamy | HEAD OF R, D, COO-NOVITIUM OPS, Dir | F - Tax | $67.67 | -1,122 | 68.7K | -2% | -$75.9K | |
| 2024-03-01 | 2024-02-29 | ANIP | CAREY STEPHEN P. | SVP, CFO | F - Tax | $67.67 | -1,914 | 189.7K | -1.0% | -$129.5K | |
| 2024-03-01 | 2024-02-29 | ANIP | Marken James G. | SVP OPS, PROD DEV | F - Tax | $67.67 | -1,058 | 148.8K | -0.7% | -$71.6K | |
| 2024-03-01 | 2024-02-29 | ANIP | Lalwani Nikhil | Pres, CEO, Dir | F - Tax | $67.67 | -10.0K | 473.9K | -2% | -$677.6K | |
| 2024-03-01 | 2024-02-29 | ANIP | Cook Meredith | SVP, GC, SEC | F - Tax | $67.67 | -1,173 | 60.2K | -2% | -$79.4K | |
| 2024-03-01 | 2024-02-29 | ANIP | Mutz Christopher | HEAD OF RARE DISEASE | F - Tax | $67.67 | -1,275 | 92.4K | -1% | -$86.3K | |
| 2024-03-01 | 2024-02-29 | ANIP | Gutwerg Ori | SVP, GENERICS | F - Tax | $67.67 | -1,570 | 82.7K | -2% | -$106.2K | |
| 2024-03-01 | 2024-02-29 | ANIP | Gassert Chad | SVP - CORP. DEV, STRATEGY | F - Tax | $67.67 | -1,635 | 49.7K | -3% | -$110.6K | |
| 2024-03-01 | 2024-02-29 | ANIP | Davis Krista | SVP, Chief HR Off | F - Tax | $67.67 | -1,173 | 51.5K | -2% | -$79.4K | |
| 2024-02-20 | 2024-02-15 | ANIP | Mutz Christopher | HEAD OF RARE DISEASE | F - Tax | $57.55 | -1,261 | 93.7K | -1% | -$72.6K | |
| 2024-02-20 | 2024-02-15 | ANIP | Gutwerg Ori | SVP, GENERICS | F - Tax | $57.55 | -1,244 | 84.3K | -1% | -$71.6K | |
| M | 2024-02-16 | 2024-02-14 | ANIP | Gassert Chad | SVP - CORP. DEV, STRATEGY | A - Grant | $0.00 | +22.4K | 51.3K | +77% | $0 |
| M | 2024-02-16 | 2024-02-14 | ANIP | Shanmugam Muthusamy | HEAD OF R, D, COO-NOVITIUM OPS, Dir | A - Grant | $0.00 | +22.4K | 69.8K | +47% | $0 |
| M | 2024-02-16 | 2024-02-14 | ANIP | CAREY STEPHEN P. | SVP, CFO | A - Grant | $0.00 | +35.8K | 177.3K | +25% | $0 |
| M | 2024-02-16 | 2024-02-14 | ANIP | Gutwerg Ori | SVP, GENERICS | A - Grant | $0.00 | +24.6K | 75.7K | +48% | $0 |
| M | 2024-02-16 | 2024-02-14 | ANIP | Cook Meredith | SVP, GC, SEC | A - Grant | $0.00 | +24.6K | 51.6K | +91% | $0 |
| M | 2024-02-16 | 2024-02-14 | ANIP | Mutz Christopher | HEAD OF RARE DISEASE | A - Grant | $0.00 | +31.3K | 94.9K | +49% | $0 |
| M | 2024-02-16 | 2024-02-14 | ANIP | Marken James G. | SVP OPS, PROD DEV | A - Grant | $0.00 | +16.8K | 149.9K | +13% | $0 |
| M | 2024-02-16 | 2024-02-14 | ANIP | Lalwani Nikhil | Pres, CEO, Dir | A - Grant | $0.00 | +134.2K | 484.0K | +38% | $0 |
| M | 2024-02-16 | 2024-02-14 | ANIP | Davis Krista | SVP, Chief HR Off | A - Grant | $0.00 | +20.1K | 52.7K | +62% | $0 |
| 2024-02-13 | 2024-02-13 | ANIP | Cook Meredith | SVP, GC, SEC | S - Sale | $56.04 | -250 | 36.8K | -0.7% | -$14.0K | |
| MI | 2024-01-23 | 2024-01-19+ | ANIP | Shanmugam Muthusamy | HEAD OF R, D, COO-NOVITIUM OPS, Dir | S - Sale | $56.17 | -25.2K | 882.6K | -3% | -$1.42M |
| MI | 2024-01-18 | 2024-01-16+ | ANIP | Shanmugam Muthusamy | HEAD OF R, D, COO-NOVITIUM OPS, Dir | S - Sale | $55.29 | -24.8K | 907.8K | -3% | -$1.37M |
| 2024-01-16 | 2024-01-12 | ANIP | Cook Meredith | SVP, GC, SEC | S - Sale | $56.43 | -250 | 37.0K | -0.7% | -$14.1K | |
| MI | 2023-12-19 | 2023-12-15+ | ANIP | Shanmugam Muthusamy | HEAD OF R, D, COO-NOVITIUM OPS, Dir | S - Sale | $52.55 | -50.0K | 957.6K | -5% | -$2.63M |
| 2023-12-11 | 2023-12-11 | ANIP | Cook Meredith | SVP, GC, SEC | S - Sale | $49.21 | -250 | 37.3K | -0.7% | -$12.3K | |
| MAI | 2023-11-20 | 2023-11-14+ | ANIP | Shanmugam Muthusamy | HEAD OF R, D, COO-NOVITIUM OPS, Dir | S - Sale | $53.00 | -37.0K | 995.6K | -4% | -$1.96M |
| I | 2023-11-20 | 2023-11-17 | ANIP | Shanmugam Muthusamy | HEAD OF R, D, COO-NOVITIUM OPS, Dir | S - Sale | $51.00 | -13.0K | 982.6K | -1% | -$663.0K |
| 2023-11-16 | 2023-11-15 | ANIP | Davis Krista | SVP, Chief HR Off | S - Sale | $53.81 | -2,622 | 32.6K | -7% | -$141.1K | |
| MI | 2023-11-16 | 2023-11-14+ | ANIP | Shanmugam Muthusamy | HEAD OF R, D, COO-NOVITIUM OPS, Dir | S - Sale | $53.00 | -36.2K | 1.00M | -3% | -$1.92M |
| 2023-11-14 | 2023-11-13 | ANIP | Cook Meredith | SVP, GC, SEC | S - Sale | $52.03 | -250 | 37.5K | -0.7% | -$13.0K | |
| 2023-11-13 | 2023-11-10 | ANIP | Mutz Christopher | HEAD OF RARE DISEASE | S - Sale | $52.47 | -3,000 | 63.6K | -5% | -$157.4K | |
| MI | 2023-10-19 | 2023-10-17+ | ANIP | Shanmugam Muthusamy | HEAD OF R, D, COO-NOVITIUM OPS, Dir | S - Sale | $57.75 | -25.0K | 1.05M | -2% | -$1.44M |
| MI | 2023-10-17 | 2023-10-13+ | ANIP | Shanmugam Muthusamy | HEAD OF R, D, COO-NOVITIUM OPS, Dir | S - Sale | $57.96 | -25.0K | 1.06M | -2% | -$1.45M |
| I | 2023-10-03 | 2023-10-02 | ANIP | Gassert Chad | SVP - CORP. DEV, STRATEGY | S - Sale | $56.48 | -20.0K | 293.2K | -6% | -$1.13M |
| MI | 2023-09-19 | 2023-09-15+ | ANIP | Shanmugam Muthusamy | HEAD OF R, D, COO-NOVITIUM OPS, Dir | S - Sale | $61.81 | -50.0K | 1.08M | -4% | -$3.09M |
| 2023-09-14 | 2023-09-12 | ANIP | Davis Krista | SVP, Chief HR Off | F - Tax | $61.91 | -1,486 | 35.2K | -4% | -$92.0K | |
| 2023-09-11 | 2023-09-08 | ANIP | Lalwani Nikhil | Pres, CEO, Dir | F - Tax | $61.94 | -3,646 | 349.7K | -1% | -$225.8K | |
| I | 2023-09-05 | 2023-09-01 | ANIP | Gassert Chad | SVP - CORP. DEV, STRATEGY | S - Sale | $64.70 | -20.0K | 313.2K | -6% | -$1.29M |
| MI | 2023-08-30 | 2023-08-28+ | ANIP | Shanmugam Muthusamy | HEAD OF R, D, COO-NOVITIUM OPS, Dir | S - Sale | $63.22 | -50.0K | 1.13M | -4% | -$3.16M |
| DM | 2023-08-25 | 2023-08-23 | ANIP | Marken James G. | SVP OPS, PROD DEV | M - OptEx | $38.25 | +5,417 | 135.4K | +4% | +$207.2K |
| D | 2023-08-25 | 2023-08-23 | ANIP | Marken James G. | SVP OPS, PROD DEV | S - Sale+OE | $63.00 | -3,932 | 133.1K | -3% | -$247.7K |
| DM | 2023-08-25 | 2023-08-23 | ANIP | Gutwerg Ori | SVP, GENERICS | S - Sale+OE | $62.39 | -15.6K | 63.0K | -20% | -$970.9K |
| D | 2023-08-25 | 2023-08-23 | ANIP | Gutwerg Ori | SVP, GENERICS | M - OptEx | $31.49 | +13.5K | 76.5K | +21% | +$425.2K |
| 2023-08-23 | 2023-08-21 | ANIP | Leonard Matthew J | Dir | A - Grant | $0.00 | +7,583 | 7,583 | New | $0 | |
| 2023-08-16 | 2023-08-14 | ANIP | CAREY STEPHEN P. | SVP, CFO | S - Sale | $61.37 | -17.6K | 155.8K | -10% | -$1.08M | |
| 2023-08-16 | 2023-08-16 | ANIP | MERIDIAN VENTURE PARTNERS II LP | 10% | S - Sale | $58.50 | -200.0K | 1.82M | -10% | -$11.70M | |
| MI | 2023-08-16 | 2023-08-14+ | ANIP | Shanmugam Muthusamy | HEAD OF R, D, COO-NOVITIUM OPS, Dir | S - Sale | $61.35 | -50.0K | 1.20M | -4% | -$3.07M |
| 2023-08-15 | 2023-08-14 | ANIP | Pera Antonio R | Dir | S - Sale | $60.37 | -3,000 | 33.6K | -8% | -$181.1K | |
| D | 2023-08-15 | 2023-08-15 | ANIP | Lalwani Nikhil | Pres, CEO, Dir | M - OptEx | $29.00 | +11.6K | 365.0K | +3% | +$336.9K |
| DM | 2023-08-15 | 2023-08-11+ | ANIP | Lalwani Nikhil | Pres, CEO, Dir | S - Sale+OE | $58.32 | -68.3K | 353.4K | -16% | -$3.98M |
| I | 2023-08-03 | 2023-08-01 | ANIP | Gassert Chad | SVP - CORP. DEV, STRATEGY | S - Sale | $51.06 | -20.0K | 333.2K | -6% | -$1.02M |
| MI | 2023-07-21 | 2023-07-19+ | ANIP | Shanmugam Muthusamy | HEAD OF R, D, COO-NOVITIUM OPS, Dir | S - Sale | $52.02 | -23.5K | 1.23M | -2% | -$1.22M |
| 2023-07-19 | 2023-07-18 | ANIP | Cook Meredith | SVP, GC, SEC | F - Tax | $51.89 | -1,743 | 37.8K | -4% | -$90.4K | |
| MI | 2023-07-18 | 2023-07-14+ | ANIP | Shanmugam Muthusamy | HEAD OF R, D, COO-NOVITIUM OPS, Dir | S - Sale | $51.02 | -26.5K | 1.26M | -2% | -$1.35M |
| I | 2023-07-06 | 2023-07-03 | ANIP | Gassert Chad | SVP - CORP. DEV, STRATEGY | S - Sale | $53.43 | -20.0K | 353.2K | -5% | -$1.07M |
| MAI | 2023-06-23 | 2023-06-20+ | ANIP | Shanmugam Muthusamy | HEAD OF R, D, COO-NOVITIUM OPS, Dir | S - Sale | $51.70 | -50.0K | 1.32M | -4% | -$2.58M |
| I | 2023-06-23 | 2023-06-22 | ANIP | Gassert Chad | SVP - CORP. DEV, STRATEGY | S - Sale | $51.32 | -20.0K | 373.2K | -5% | -$1.03M |
| M | 2023-06-22 | 2023-06-20+ | ANIP | Shanmugam Muthusamy | HEAD OF R, D, COO-NOVITIUM OPS, Dir | S - Sale | $51.75 | -40.0K | 20.9K | -66% | -$2.07M |
| 2023-05-24 | 2023-05-23 | ANIP | Walsh Patrick D | Dir | A - Grant | $0.00 | +6,865 | 70.3K | +11% | $0 | |
| 2023-05-24 | 2023-05-23 | ANIP | NASH DAVID | Dir | A - Grant | $0.00 | +6,865 | 38.6K | +22% | $0 | |
| 2023-05-24 | 2023-05-23 | ANIP | Pera Antonio R | Dir | A - Grant | $0.00 | +6,865 | 36.6K | +23% | $0 | |
| 2023-05-24 | 2023-05-23 | ANIP | HAUGHEY THOMAS | Dir | A - Grant | $0.00 | +6,865 | 47.1K | +17% | $0 | |
| 2023-05-24 | 2023-05-23 | ANIP | TANNENBAUM RENEE P | Dir | A - Grant | $0.00 | +6,865 | 20.2K | +51% | $0 | |
| 2023-05-24 | 2023-05-23 | ANIP | Thoma Jeanne | Dir | A - Grant | $0.00 | +6,865 | 36.2K | +23% | $0 | |
| 2023-04-12 | 2023-04-10 | ANIP | Marken James G. | SVP OPS, PROD DEV | F - Tax | $38.50 | -2,289 | 131.6K | -2% | -$88.1K | |
| 2023-04-12 | 2023-04-10 | ANIP | CAREY STEPHEN P. | SVP, CFO | F - Tax | $38.50 | -4,534 | 173.5K | -3% | -$174.6K | |
| M | 2023-04-06 | 2023-02-28 | ANIP | CAREY STEPHEN P. | SVP, CFO | A - Grant | $0.00 | +40.5K | 178.0K | +29% | $0 |
| M | 2023-04-04 | 2023-02-28 | ANIP | Marken James G. | SVP OPS, PROD DEV | A - Grant | $0.00 | +21.7K | 133.9K | +19% | $0 |
| M | 2023-04-04 | 2023-02-28 | ANIP | Gassert Chad | SVP - CORP. DEV, STRATEGY | A - Grant | $0.00 | +28.9K | 28.9K | New | $0 |
| M | 2023-04-04 | 2023-02-28 | ANIP | Lalwani Nikhil | Pres, CEO, Dir | A - Grant | $0.00 | +159.2K | 346.4K | +85% | $0 |
| M | 2023-04-04 | 2023-02-28 | ANIP | Shanmugam Muthusamy | HEAD OF R, D, COO-NOVITIUM OPS, Dir | A - Grant | $0.00 | +28.9K | 47.4K | +157% | $0 |
| M | 2023-04-04 | 2023-02-28 | ANIP | Mutz Christopher | HEAD OF RARE DISEASE | A - Grant | $0.00 | +28.9K | 55.0K | +111% | $0 |
| M | 2023-04-04 | 2023-02-28 | ANIP | Cook Meredith | SVP, GC, SEC | A - Grant | $0.00 | +20.3K | 39.5K | +105% | $0 |
| M | 2023-04-04 | 2023-02-28 | ANIP | Davis Krista | SVP, Chief HR Off | A - Grant | $0.00 | +20.3K | 36.7K | +123% | $0 |
| M | 2023-04-04 | 2023-02-28 | ANIP | Gutwerg Ori | SVP, GENERICS | A - Grant | $0.00 | +28.9K | 63.0K | +85% | $0 |
| 2023-03-30 | 2023-03-28 | ANIP | Marken James G. | SVP OPS, PROD DEV | F - Tax | $38.62 | -524 | 112.2K | -0.5% | -$20.2K |
Purchase Sale Sale after option exercise All abbreviations